Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2004 February;56(1) > Minerva Ginecologica 2004 February;56(1):91-104

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Ginecologica 2004 February;56(1):91-104

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: Italian

Biologic therapy and epithelial ovarian cancer

Porpiglia M., Vicelli R., Durando A., Fracchioli S., Puopolo M., Katsaros D., Bellino R., Benedetto C.


PDF  


The identification of new molecular prognostic and predictive factors for ovarian cancer may contribute in deciding individual therapeutic strategies; on the other hand, there has been growing interest in new biologic therapies to correct molecular or genic lesions of neoplastic cells (genic therapy), or to activate the specific immune response (immunological therapy). Chemotherapy collateral toxic effects, as myelotoxicity, should be reduced through transfection of genes that modulate drug resistance in stem cells. The data at present available suggest then the potential role of these new treatments, are more specific and less toxic than current therapies; hovewer, other biological-molecular studies are required to obtain the clinical applications of the results. Aim of this study is to provide a review of the most interesting data in ovarian cancer biologic therapy.

top of page

Publication History

Cite this article as

Corresponding author e-mail